Acropolis Investment Management LLC lifted its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 6.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,049 shares of the biopharmaceutical company’s stock after buying an additional 520 shares during the period. Acropolis Investment Management LLC’s holdings in Bristol-Myers Squibb were worth $459,000 at the end of the most recent reporting period.
A number of other large investors have also recently made changes to their positions in the business. Fox Run Management L.L.C. purchased a new position in Bristol-Myers Squibb in the third quarter worth about $344,000. Surevest Inc. boosted its position in Bristol-Myers Squibb by 32.3% in the third quarter. Surevest Inc. now owns 19,333 shares of the biopharmaceutical company’s stock worth $980,000 after purchasing an additional 4,716 shares during the last quarter. Biegel & Waller LLC boosted its position in Bristol-Myers Squibb by 10.4% in the third quarter. Biegel & Waller LLC now owns 5,300 shares of the biopharmaceutical company’s stock worth $269,000 after purchasing an additional 500 shares during the last quarter. IFG Advisors LLC purchased a new position in Bristol-Myers Squibb in the third quarter worth about $306,000. Finally, Sabal Trust CO boosted its position in Bristol-Myers Squibb by 61.3% in the third quarter. Sabal Trust CO now owns 14,316 shares of the biopharmaceutical company’s stock worth $726,000 after purchasing an additional 5,441 shares during the last quarter. 80.25% of the stock is currently owned by institutional investors and hedge funds.
NYSE BMY traded up $0.46 during trading hours on Tuesday, hitting $52.02. The company had a trading volume of 3,295,297 shares, compared to its average volume of 10,084,974. Bristol-Myers Squibb Co has a fifty-two week low of $42.48 and a fifty-two week high of $59.28. The company has a market capitalization of $84.34 billion, a price-to-earnings ratio of 13.07, a P/E/G ratio of 2.54 and a beta of 0.72. The company has a debt-to-equity ratio of 1.51, a current ratio of 3.88 and a quick ratio of 3.75. The firm’s 50 day moving average is $49.59 and its 200 day moving average is $47.11.
The business also recently declared a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be given a dividend of $0.41 per share. The ex-dividend date is Thursday, October 3rd. This represents a $1.64 annualized dividend and a dividend yield of 3.15%. Bristol-Myers Squibb’s payout ratio is 41.21%.
In other Bristol-Myers Squibb news, Director Robert J. Bertolini bought 11,000 shares of the business’s stock in a transaction on Wednesday, July 31st. The shares were purchased at an average price of $44.72 per share, with a total value of $491,920.00. Following the completion of the acquisition, the director now directly owns 11,397 shares of the company’s stock, valued at approximately $509,673.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.13% of the company’s stock.
Several research analysts have issued reports on BMY shares. Atlantic Securities raised Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 target price on the stock in a research report on Wednesday, August 14th. JPMorgan Chase & Co. set a $62.00 target price on Bristol-Myers Squibb and gave the company a “buy” rating in a research report on Friday, September 13th. TheStreet upgraded Bristol-Myers Squibb from a “c+” rating to a “b-” rating in a report on Wednesday, September 18th. ValuEngine raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Monday, October 7th. Finally, Bank of America upped their target price on Bristol-Myers Squibb from $49.00 to $50.00 and gave the company a “neutral” rating in a research report on Thursday, October 10th. Eight equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $55.81.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Read More: Do You Need a Fiduciary?
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.